Close Menu
The Financial News 247The Financial News 247
  • Home
  • News
  • Business
  • Finance
  • Companies
  • Investing
  • Markets
  • Lifestyle
  • Tech
  • More
    • Opinion
    • Climate
    • Web Stories
    • Spotlight
    • Press Release
What's On

Why Chase, Microsoft and United are facing crippling outages — and why it’ll get worse

November 16, 2026

JPMorgan Chase says in-house software issue impacted service — and possibly other banks

November 16, 2026

Berkshire Hathaway cuts stakes in Bank of American, Capital One

November 16, 2026

How To Keep CRM And ERP Silos From Killing Operational Efficiency

November 16, 2026

Exclusive | LA sheriff cuts ties with charity run by top NY tax cheat Daniel Gordon –

November 16, 2026
Facebook X (Twitter) Instagram
The Financial News 247The Financial News 247
Demo
  • Home
  • News
  • Business
  • Finance
  • Companies
  • Investing
  • Markets
  • Lifestyle
  • Tech
  • More
    • Opinion
    • Climate
    • Web Stories
    • Spotlight
    • Press Release
The Financial News 247The Financial News 247
Home » CVS says GLP-1s save money when priced below $350 per month

CVS says GLP-1s save money when priced below $350 per month

By News RoomNovember 15, 2026No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn WhatsApp Telegram Reddit Email Tumblr
Share
Facebook Twitter LinkedIn Pinterest Email

CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month as reduced use of medical services, such as hospitalizations and emergency room visits, lower spending enough to offset drug costs.

CVS said that an analysis of its Aetna insurance claims data found that across patients with obesity, diabetes or other conditions, the current prices for GLP-1 drugs add to spending because they are too high to be impacted by lower medical costs.

The analysis looked at patients who were newly taking highly popular GLP-1 medicines — which mimic the GLP-1 hormone and reduce appetite — from Eli Lilly and Novo Nordisk, and compared them to similar patients who were not taking the drugs.

A person holding weight loss injection pens including Wegovy, Ozempic, and Mounjaro.
CVS Health said lower-priced GLP-drugs could lead to savings for employers and other health plan sponsors through reduced use of medical services.

The drugs included Mounjaro and Ozempic for diabetes and Zepbound and Wegovy for obesity. The analysis covered periods of up to three years, with patients starting the medicines between 2023 and 2025.

The analysis did not break out figures for obesity patients alone.

Coverage of GLP-1 drugs for obesity is falling as corporations and other health plan sponsors try to bring down premiums expected to be up by over 9% in 2027. About 14% of companies have already dropped or plan to drop the drugs in 2027.

Zepbound and Wegovy can cost about $299 and $349 for cash-pay customers. Employers and other health plan sponsors pay between $617 and $766 monthly for the drugs, according to a 2025 study by the Employee Benefit Research Institute. CVS declined to comment on the average prices paid.

Dr. Amy Compton-Phillips, chief medical officer at CVS Health, said that the drugmakers’ direct-to-consumer prices suggest they can still profit by charging less than $350 a month, while also helping to lower overall health care costs. The US pays more for health care than any other country.

“I hope that we can reach that price sooner rather than later,” she said in an interview ahead of the HLTH USA conference in Las Vegas, where CVS will present the findings on Sunday.

Illustration of the CVS Health logo.
GLP-1 use for obesity, diabetes or other conditions was associated with 10%-12% lower emergency room visits in the first and second year of use, according to CVS Health.

The US government agreed on a deal with Lilly and Novo last year to pay $245 per month for injectable GLP-1 weight-loss drugs in an 18-month pilot testing their cost-effectiveness for Medicare beneficiaries aged 65 and older or with disabilities.

CVS said GLP-1 use for obesity, diabetes or other conditions was associated with 10%-12% lower emergency room visits in the first and second year of use. It examined records for 60,000 people during the first year and 20,000 people for a second year.

An analysis of records for 4,000 people still taking the drug after three years showed a decrease in hospitalizations of 34-42%, according to the report.

When looking at spending and savings across those three years, plan sponsors saved $9,400 per person on medical bills, but spent $13,300 more on prescriptions, adding costs of $3,900 per person.

The company, which also operates pharmacy benefit manager Caremark and a network of retail pharmacies it plans to spin off, said the price at which GLP-1s start saving money overall depends on how healthy or sick a patient is.

“An older person with diabetes is going to have a higher risk for hospitalization than a younger person who is obese without diabetes,” said Compton-Phillips. “The higher-risk the person is, the quicker you get to a return on investment.”

Business cvs glp-1 pharmaceuticals
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related News

Why Chase, Microsoft and United are facing crippling outages — and why it’ll get worse

November 16, 2026

JPMorgan Chase says in-house software issue impacted service — and possibly other banks

November 16, 2026

Berkshire Hathaway cuts stakes in Bank of American, Capital One

November 16, 2026

Exclusive | LA sheriff cuts ties with charity run by top NY tax cheat Daniel Gordon –

November 16, 2026

OpenAI CEO Sam Altman empathizes with Nvidia’s Jensen Huang: ‘Heroes have flaws’

November 16, 2026

OpenAI sued by California over hacking incidents on Hugging Face, other companies

November 16, 2026
Add A Comment
Leave A Reply Cancel Reply

Don't Miss

JPMorgan Chase says in-house software issue impacted service — and possibly other banks

Business November 16, 2026

JPMorgan Chase said Monday that a software bug in systems it runs in-house slowed service…

Berkshire Hathaway cuts stakes in Bank of American, Capital One

November 16, 2026

How To Keep CRM And ERP Silos From Killing Operational Efficiency

November 16, 2026

Exclusive | LA sheriff cuts ties with charity run by top NY tax cheat Daniel Gordon –

November 16, 2026
Stay In Touch
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
Our Picks

OpenAI CEO Sam Altman empathizes with Nvidia’s Jensen Huang: ‘Heroes have flaws’

November 16, 2026

Turning Your Business Into An AI Lab Before Selling It To Clients

November 16, 2026

OpenAI sued by California over hacking incidents on Hugging Face, other companies

November 16, 2026

How To Combine External And Proprietary Data Without Losing Control

November 16, 2026
The Financial News 247
Facebook X (Twitter) Instagram Pinterest
  • Privacy Policy
  • Terms of use
  • Advertise
  • Contact us
© 2026 The Financial 247. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.